NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PROCANBID (procainamide hydrochloride) by Pfizer is clinical pharmacology procainamide (pa) increases the effective refractory period of the atria, and to a lesser extent the bundle of his-purkinje system and ventricles of the heart. Approved for documented ventricular arrhythmias, such, that and 1 more indications. First approved in 1996.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROCANBID is an oral extended-release formulation of procainamide hydrochloride, a Class IA antiarrhythmic agent approved for documented ventricular arrhythmias. It works by increasing the effective refractory period of cardiac tissue, slowing conduction velocity, and reducing myocardial excitability to suppress ectopic pacemaker activity. The drug reaches therapeutic plasma levels in 90–120 minutes via oral administration with a half-life of 3–4 hours in patients with normal renal function.
LOE Approaching
Product approaching loss of exclusivity with minimal Part D spending data; brand team likely focused on managed decline and generic transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Procainamide (PA) increases the effective refractory period of the atria, and to a lesser extent the bundle of His-Purkinje system and ventricles of the heart. It reduces impulse conduction velocity in the atria, His-Purkinje fibers, and ventricular muscle, but has variable…
Worked on PROCANBID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.